tiprankstipranks
Advertisement
Advertisement

CH:BIOV Stock Latest News

BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
Company AnnouncementsBioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
7d ago
BIOV
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
PremiumCompany Announcements
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
16d ago
BIOV
Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
PremiumRatings
Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
21d ago
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
PremiumCompany Announcements
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
22d ago
BIOV
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
PremiumCompany Announcements
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
23d ago
BIOV
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
PremiumRatingsBioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
25d ago
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
Premium
Company Announcements
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
25d ago
BIOV
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
Premium
Company Announcements
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
1M ago
BIOV
BioVersys Strengthens Investor Outreach With New IR and Communications Head
PremiumCompany Announcements
BioVersys Strengthens Investor Outreach With New IR and Communications Head
1M ago
BIOV
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
PremiumRatings
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
1M ago
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
PremiumCompany Announcements
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
1M ago
BIOV
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
PremiumCompany Announcements
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
2M ago
BIOV
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
PremiumRatingsBioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
2M ago
BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
Premium
Company Announcements
BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
2M ago
BIOV
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
Premium
Ratings
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
2M ago
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
PremiumCompany Announcements
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
2M ago
BIOV
BioVersys Sets Date for 2025 Results as Late‑Stage Antibacterial Pipeline Advances
PremiumCompany Announcements
BioVersys Sets Date for 2025 Results as Late‑Stage Antibacterial Pipeline Advances
2M ago
BIOV
BioVersys Advances BV100 Antibiotic as Phase 1 Data Published and Global Pivotal Trial Starts
PremiumCompany Announcements
BioVersys Advances BV100 Antibiotic as Phase 1 Data Published and Global Pivotal Trial Starts
2M ago
BIOV
BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis
PremiumCompany Announcements
BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis
2M ago
BIOV
BioVersys Advances BV100 Into Phase IIb for Drug-Resistant Hospital Infections
PremiumCompany AnnouncementsBioVersys Advances BV100 Into Phase IIb for Drug-Resistant Hospital Infections
2M ago
BIOV
BioVersys gains key TB proof-of-concept as AlpE Phase 2a data land in NEJM
Premium
Company Announcements
BioVersys gains key TB proof-of-concept as AlpE Phase 2a data land in NEJM
3M ago
BIOV
BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch
Premium
Company Announcements
BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch
4M ago
BIOV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >